Our Pricing

Wegovy Maintenance Dose: Real UK Weight Loss Evidence

Published on: June 03, 2026

Understanding wegovy maintenance dose uk results is crucial for long-term weight management success. At Cured Pharmacy, our UK clinical team has supported thousands of patients through the complete Wegovy journey, from initial titration to sustained maintenance at 2.4mg, with genuine UK-licensed medication from £79.00 and transparent clinical guidance throughout.

What Is the Wegovy Maintenance Dose and When Do You Reach It?

The Wegovy maintenance dose is 2.4mg semaglutide administered once weekly via subcutaneous injection. This represents the full therapeutic dose licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Patients typically reach this maintenance dose after 16-20 weeks of gradual dose escalation, starting from 0.25mg and increasing through 0.5mg, 1mg, and 1.7mg stages.

The titration schedule exists to minimise gastrointestinal side effects whilst your body adapts to semaglutide's effects on gastric emptying and appetite regulation. In the STEP clinical trial programme, this gradual escalation protocol resulted in significantly lower discontinuation rates compared to rapid dose increases [1]. Your UK prescriber may adjust this timeline based on individual tolerability and response.

Once you've maintained the 2.4mg dose for at least four consecutive weeks without significant adverse effects, you've entered the maintenance phase. This is when the focus shifts from dose escalation to sustained weight management and metabolic optimisation through continued weekly injections.

Clinical Evidence: Wegovy Maintenance Dose UK Results from STEP Trials

The STEP 1 trial provides the most comprehensive data on wegovy maintenance dose uk results, following 1,961 adults over 68 weeks. Participants who reached and maintained the 2.4mg dose achieved an average body weight reduction of 14.9% from baseline, compared to 2.4% with placebo [1]. Critically, 83.5% of patients on the maintenance dose lost at least 5% of their body weight, and 66.1% achieved at least 10% reduction.

What's particularly relevant for UK patients is the sustained effect during the maintenance phase. Between week 20 (when most participants reached 2.4mg) and week 68, weight continued to decrease gradually before plateauing around week 60 [2]. This demonstrates that the maintenance dose doesn't simply prevent weight regain — it continues to facilitate modest additional weight loss for several months after reaching the target dose.

The STEP 4 trial examined what happens when patients discontinue Wegovy after reaching maintenance. Participants who stopped treatment regained approximately two-thirds of their lost weight within 48 weeks, whilst those continuing the 2.4mg maintenance dose sustained their weight loss with minimal regain [2]. This evidence underscores the importance of viewing Wegovy as a long-term treatment rather than a short-term intervention.

Real-World UK Patient Outcomes

Whilst clinical trials provide controlled evidence, real-world UK data shows slightly more variable results. Factors including adherence to weekly injections, concurrent lifestyle modifications, baseline metabolic health, and individual response to semaglutide all influence maintenance dose effectiveness. Our clinical team at Cured Pharmacy observes that patients who combine the 2.4mg maintenance dose with structured dietary changes and regular physical activity typically achieve results consistent with or exceeding STEP trial averages.

Managing Weight Plateaus on Wegovy 2.4mg Maintenance Dose

Experiencing a weight plateau after several months on the wegovy maintenance dose is physiologically normal and doesn't indicate treatment failure. Your body's metabolic rate naturally adjusts to lower body weight, reducing the caloric deficit that initially drove weight loss [3]. Additionally, as you lose weight, your total daily energy expenditure decreases, requiring further dietary adjustments to maintain the same rate of loss.

Clinical evidence suggests that weight typically stabilises between weeks 60-68 on the 2.4mg maintenance dose, with most patients maintaining this reduced weight rather than continuing to lose indefinitely [1]. If you reach a plateau earlier than expected, your UK prescriber may assess whether you've achieved a clinically meaningful weight loss (typically 5% or more), evaluate adherence to injection schedule, and discuss whether adjusting lifestyle factors might restart progress.

It's important to distinguish between a true plateau (no weight change for 8-12 weeks) and normal weekly fluctuations. Water retention, menstrual cycle changes, sodium intake, and muscle gain from increased activity can all mask fat loss on the scales. Some patients benefit from tracking additional metrics like waist circumference, body composition, or metabolic markers including HbA1c and lipid profiles during the maintenance phase.

When to Consider Treatment Adjustments

If you've maintained the 2.4mg dose for 6 months without achieving at least 5% body weight reduction, your prescriber may reassess whether Wegovy remains the optimal treatment. NICE guidance suggests considering alternative interventions if adequate response isn't achieved, though individual circumstances vary considerably. Some patients may benefit from switching to dual-action treatments, whilst others achieve better results by addressing underlying factors like sleep quality, stress management, or undiagnosed metabolic conditions.

How Long Should You Stay on Wegovy Maintenance Dose?

Current MHRA licensing and clinical evidence support indefinite continuation of the wegovy 2.4mg maintenance dose for chronic weight management, provided the treatment remains effective and well-tolerated. Unlike short-term weight loss interventions, semaglutide addresses the underlying neurohormonal dysregulation that drives weight regain after diet-induced weight loss [4].

The longest published trial data extends to 104 weeks (approximately 2 years), demonstrating sustained weight loss maintenance throughout this period with no evidence of tolerance or diminishing effect [2]. However, many UK patients and prescribers are now approaching 3-4 years of continuous treatment as Wegovy becomes established in clinical practice, with ongoing real-world evidence suggesting sustained benefit.

The decision to continue long-term maintenance should be reviewed regularly with your UK prescriber, typically every 6-12 months. This assessment considers sustained weight loss maintenance, improvements in weight-related comorbidities (such as type 2 diabetes, hypertension, or obstructive sleep apnoea), tolerability of ongoing injections, and individual treatment goals. Some patients successfully transition to lower maintenance doses under medical supervision, though this approach lacks robust clinical trial evidence.

Wegovy Maintenance Dose vs Other Weight Loss Treatments

When evaluating wegovy maintenance dose uk results against alternative treatments, the 2.4mg semaglutide dose demonstrates superior efficacy compared to earlier GLP-1 receptor agonists. Liraglutide 3mg (marketed as Saxenda) achieved an average 8% body weight reduction over 56 weeks in the SCALE trials — approximately half the effect seen with Wegovy's maintenance dose [3].

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown even greater weight loss in head-to-head comparisons. The SURMOUNT-1 trial demonstrated that tirzepatide 15mg maintenance dose produced an average 20.9% body weight reduction over 72 weeks, compared to historical Wegovy data of approximately 15% [4]. However, tirzepatide isn't yet widely available through all UK pharmacies, and individual response varies considerably between these medications.

Oral treatments like orlistat (60mg or 120mg) typically produce 3-5% weight loss — significantly less than injectable GLP-1 therapies — but may suit patients who prefer non-injectable options or have contraindications to semaglutide [3]. The choice between treatments should be individualised based on your medical history, treatment preferences, cost considerations, and previous response to weight management interventions.

Combination Approaches During Maintenance

Some UK prescribers explore combining the Wegovy maintenance dose with complementary interventions for patients who plateau or require additional metabolic support. Whilst semaglutide monotherapy remains the evidence-based standard, emerging research examines whether adding metformin, SGLT2 inhibitors, or structured meal replacement programmes enhances long-term outcomes. Any combination approach requires careful medical supervision and isn't suitable for all patients.

Starting Your Wegovy Journey at Cured Pharmacy

At Cured Pharmacy, we provide genuine UK-licensed Wegovy with transparent pricing from £79.00, significantly lower than typical market rates. Every prescription requires a clinical assessment by our UK-registered prescribers, completed online in under 3 minutes. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) oversees all clinical services, ensuring every patient receives individualised guidance throughout their weight management journey.

Your Wegovy prescription includes the complete titration schedule from 0.25mg through to the 2.4mg maintenance dose, with ongoing clinical support as you progress through each stage. We provide discreet packaging, reliable UK delivery, and transparent communication about what to expect during both escalation and maintenance phases. All patients receive comprehensive information about injection technique, side effect management, and lifestyle optimisation strategies that enhance treatment outcomes.

As a GPhC-registered pharmacy (9012511), we dispense only genuine UK-licensed medications and maintain the highest standards of pharmaceutical care. Our clinical team remains available throughout your maintenance phase to address concerns, manage side effects, and adjust treatment plans as needed. Starting your wegovy maintenance dose uk results journey begins with a free online consultation — no hidden costs, no pressure, just expert pharmaceutical care delivered with transparency and professionalism.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
3. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence, lifestyle modifications, and metabolic response. Clinical trial data represents average outcomes and does not guarantee individual results.